Demographic and Clinical Factors Related to Severe COVID-19 Infection and Mortality in Patients With Schizophrenia

EKİNCİ O., Erkan Ekinci A.

Journal of Nervous and Mental Disease, cilt.210, sa.4, ss.257-263, 2022 (SCI-Expanded, SSCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 210 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/nmd.0000000000001500
  • Dergi Adı: Journal of Nervous and Mental Disease
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, ATLA Religion Database, BIOSIS, CAB Abstracts, Child Development & Adolescent Studies, CINAHL, Educational research abstracts (ERA), EMBASE, MEDLINE, MLA - Modern Language Association Database, Psycinfo, Violence & Abuse Abstracts
  • Sayfa Sayıları: ss.257-263
  • Anahtar Kelimeler: COVID-19, mortality, Schizophrenia, severe
  • Uşak Üniversitesi Adresli: Evet

Özet

We aimed to explore the prevalence and determinants of severe COVID-19 disease and mortality in patients with schizophrenia in this study. We conducted a retrospective observational study of 1620 patients with schizophrenia. Of the 1620 patients, 52 (3.2%) tested positive for SARS-CoV-19. Among SARS-CoV-2-positive patients, 40 patients were hospitalized, and 17 patients required intensive care unit admission due to COVID-19 (76.9% and 32.7%, respectively). Severe COVID-19 disease was noted in 17 patients (32.7%) requiring intubation. In the logistic regression analysis, antipsychotic dose, and comorbidity score were independently associated with a greater risk of severe COVID-19 disease in patients with schizophrenia. Our study suggests that factors such as age, sex, comorbidities, and a daily antipsychotic dose may have effects on the poor outcome of SARS-CoV-2 disease in schizophrenia patients. In addition, the current findings propose that mortality may be associated with an older age, comorbidity score, and a longer duration of psychiatric disease among the SARS-CoV-2-positive patients with schizophrenia. However, the findings of our study should be verified in prospective and larger sample studies.